Lixisenatide for type 2 diabetes mellitus

By Christensen Mikkel   Knop Filip K   Vilsbøøll Tina   Holst Jens J  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 4, 2011-04 ,pp. : 549-557

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes

By Forst Thomas   Pfützner Andreas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 1, 2012-01 ,pp. : 101-110

Informa Healthcare

Access to resources Recommend Favorite

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

By Russell Sheldon  

International Journal of Clinical Pharmacy, Vol. 35, Iss. 2, 2013-04 ,pp. : 159-172

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update

By Marcel M.C. Hovens   Jouke T. Tamsma   Edith D. Beishuizen   Menno V. Huisman  

Drugs, Vol. 65, Iss. 4, 2005-01 ,pp. : 433-445

Adis International

Access to resources Recommend Favorite

Safety and Tolerability of Acarbose in the Treatment of Type 1 and Type 2 Diabetes Mellitus

By Neuser Dieter  

Clinical Drug Investigation, Vol. 25, Iss. 9, 2005-01 ,pp. : 579-587

Adis International

Access to resources Recommend Favorite